GHRP-2 (Pralmorelin)

GHRP-2 is a six-part peptide that mimics ghrelin, the 'hunger hormone,' to nudge the pituitary into releasing growth hormone.

It's studied in performance research — growth-hormone reserves and how the body prevents muscle wasting.

Clinical research showed rapid growth-hormone release. It was approved as a diagnostic in Japan; broad use is unproven.

Distinguishes established clinical findings from early human trials, animal experiments, or laboratory cell culture findings. No human dosing, injection instructions, or treatment recommendations are provided.

GHRP-2 was approved in Japan as a diagnostic (Pralmorelin). It is not FDA-approved in the U.S.

BBOHC LABS research reagents are non-clinical materials. An FDA approval for a finished medicine containing the same active ingredient does not imply that BBOHC's investigational research vial is FDA-approved.

Raises cortisol and prolactin in experimental models.

• Pralmorelin human diagnostic trial summaries.

Specific citations are provided for literature context. Product purity & lot verification documentation available on request.